Danish pharmaceutical major Novo Nordisk has entered into a strategic collaboration with OpenAI to embed artificial intelligence across its drug development operations, with the stated goal of accelerating the delivery of new treatments. Announced on Tuesday, the initiative is designed to strengthen the company’s ability to identify and advance therapies more efficiently, particularly in areas such as obesity and diabetes.
Through the partnership, Novo Nordisk will deploy advanced AI systems to process and interpret complex datasets, enabling faster identification of potential drug candidates and reducing the time between early-stage research and patient access. The company stated that the Novo Nordisk OpenAI partnership will “help the company bring new and better treatment options to patients faster,” reflecting a broader push within the life sciences sector to integrate AI-driven workflows.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Mike Doustdar. He further added, “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever,” and noted, “This means discovering new therapies and bringing them to market faster than ever before.”
Beyond research, the collaboration will extend into manufacturing, supply chain, distribution, and broader corporate functions, with pilot programmes already planned across R&D, production, and commercial units. Full integration is targeted by year-end. Sam Altman said, “AI is reshaping industries and in life sciences, it can help people live better, longer lives,” adding, “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
Novo Nordisk’s expanded AI push builds on earlier initiatives, including a 2024 collaboration between the Novo Nordisk Foundation, Nvidia, and Denmark’s Export and Investment Fund to establish the Danish Centre for AI Innovation, which operates the Gefion supercomputer. The Novo Nordisk OpenAI partnership also comes amid intensifying industry activity, as pharmaceutical companies increasingly adopt AI technologies to streamline drug discovery and development processes.
In a related move, Eli Lilly announced in March 2026 a partnership with Insilico Medicine to develop and commercialise AI-discovered medicines, underscoring the growing competitive focus on artificial intelligence within the global pharmaceutical sector.
